written on 16.05.2014
Tags:
,

FDA rejects Novartis AHF drug serelaxin; more efficacy evidence needed

TAGS: ,

Dr Tim Wright, global head of development at Novartis Pharmaceuticals, said the company planned to continue to expedite its clinical trial program to build the supporting body of evidence for serelaxin per the FDA's advice.

Latest Report